within Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX26_Fexofenadine;

model Fexofenadine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.33,
    Cl = 1.5833333333333333e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.135,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01933333333333333,
    Tlag = 10.020000000000001,
    Vdp = 0.104,
    k12 = 3.638888888888889e-06,
    k21 = 3.638888888888889e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fexofenadine</td></tr><tr><td>ATC code:</td><td>R06AX26</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>135</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fexofenadine is a second-generation antihistamine used to treat allergy symptoms such as hay fever (allergic rhinitis) and urticaria (hives). It is a non-sedating antihistamine and is widely approved for clinical use globally for symptomatic relief of allergic conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Piscitelli, J, et al., &amp; Ma, JD (2023). Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach. <i>Therapeutic drug monitoring</i> 45(4) 539–545. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000001052\">10.1097/FTD.0000000000001052</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36645711/\">https://pubmed.ncbi.nlm.nih.gov/36645711</a></p></li><li><p>Pal, D, &amp; Mitra, AK (2006). MDR- and CYP3A4-mediated drug-herbal interactions. <i>Life sciences</i> 78(18) 2131–2145. DOI:<a href=\"https://doi.org/10.1016/j.lfs.2005.12.010\">10.1016/j.lfs.2005.12.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16442130/\">https://pubmed.ncbi.nlm.nih.gov/16442130</a></p></li><li><p>Simons, FE (2002). Comparative pharmacology of H1 antihistamines: clinical relevance. <i>The American journal of medicine</i> 113 Suppl 9A 38S–46S. DOI:<a href=\"https://doi.org/10.1016/s0002-9343(02)01436-5\">10.1016/s0002-9343(02)01436-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12517581/\">https://pubmed.ncbi.nlm.nih.gov/12517581</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R06AX26 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fexofenadine;
